{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:41:28Z","timestamp":1760334088469,"version":"build-2065373602"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Rhabdomyosarcoma represents a prevalent type of soft tissue sarcoma encountered in pediatric patients. Despite multimodal intensified therapies encompassing surgical intervention, chemotherapy, and radiotherapy, the prognosis for patients with high-risk rhabdomyosarcoma remains notably unfavorable. To date, no definitive and efficacious molecularly targeted therapies have been established. This report describes the first documented case of a rhabdomyosarcoma patient harboring a positive <jats:italic>BCR-ABL1<\/jats:italic> fusion gene. At the time of initial diagnosis, the patient presented with a primary tumor in the right thigh and extensive metastatic involvement affecting both lungs, pleura, mediastinum, pelvic cavity, and the right inguinal region, resulting in the classification of the case as high-risk. In addition to conventional multimodal therapy, early intervention using tyrosine kinase inhibitors was implemented, leading to the achievement of an early complete response.<\/jats:p>","DOI":"10.3389\/fmed.2025.1693688","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:27:13Z","timestamp":1760333233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Management of a BCR-ABL1-positive high-risk rhabdomyosarcoma patient using tyrosine kinase inhibitors"],"prefix":"10.3389","volume":"12","author":[{"given":"Fan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dapeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzhi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.2015.63.4048","article-title":"Intensive multiagent therapy, including dose-compressed cycles of ifosfamide\/etoposide and vincristine\/doxorubicin\/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the children's oncology group","volume":"34","author":"Weigel","year":"2016","journal-title":"J Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1002\/cam4.2504","article-title":"Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the children's oncology group","volume":"8","author":"Hibbitts","year":"2019","journal-title":"Cancer Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1200\/JCO.20.03060","article-title":"Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium","volume":"39","author":"Shern","year":"2021","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7480","DOI":"10.1073\/pnas.86.19.7480","article-title":"A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting","volume":"86","author":"Scrable","year":"1989","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.19.00576","article-title":"Randomized phase II trial of bevacizumab or temsirolimus in combination with chemotherapy for first relapse rhabdomyosarcoma: a report from the children's oncology group","volume":"37","author":"Mascarenhas","year":"2019","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S1470-2045(24)00255-9","article-title":"Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the children's oncology group","volume":"25","author":"Gupta","year":"2024","journal-title":"Lancet Oncol."},{"key":"B7","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst."},{"key":"B8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/0092-8674(80)90554-1","article-title":"Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA","volume":"22","author":"Goff","year":"1980","journal-title":"Cell."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","article-title":"Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005","volume":"28","author":"Aric\u00f2","year":"2010","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.2169\/internalmedicine.7066-21","article-title":"BCR\/ABL1-positive B-lymphoblastic Lymphoma successfully treated with dasatinib-combined chemotherapy","volume":"60","author":"Yamada","year":"2021","journal-title":"Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/his.14563","article-title":"BCR::ABL1-positive histiocytic sarcoma of the small intestine in a patient with chronic myeloid leukaemia","volume":"80","author":"Minato","year":"2022","journal-title":"Histopathology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.14740\/jocmr2566w","article-title":"Extramedullary Involvement by chronic myelogeneous leukemia in five patients with unusual clinicopathologic features: a review of the effectiveness of tyrosine kinase inhibitors","volume":"8","author":"Soni","year":"2016","journal-title":"J Clin Med Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"PO","DOI":"10.1200\/PO.20.00519","article-title":"Report of canonical BCR-ABL1 fusion in glioblastoma","volume":"5","author":"Pang","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu Rev Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun TP Eide","year":"2020","journal-title":"Cancer Cell."},{"key":"B18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14737159.2017.1275965","article-title":"Molecular diagnostics in the management of rhabdomyosarcoma","volume":"17","author":"Arnold","year":"2017","journal-title":"Expert Rev Mol Diagn."},{"key":"B19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/PAS.0000000000000538","article-title":"A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases","volume":"40","author":"Alaggio","year":"2016","journal-title":"Am J Surg Pathol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1693688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:27:16Z","timestamp":1760333236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1693688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":19,"alternative-id":["10.3389\/fmed.2025.1693688"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1693688","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1693688"}}